Search Results
26 results found-
OFR 1 Chair and CEO message 2 8 Environment 46 2 Our Company 8 9 Social 53 3 CSL's Performance and Strategy 20 OFR 10 CSL's Governance 60 4 CSL's Material Risks 26 11 Share Information 70 5 CSL's Future Prospects 28 12 Key Performance Data Summary 73 6 Powered by Innovation 32 13 Medical Glossary 74 7 CSL's People 40 OFR 14 Financial Performance 75
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
Limit the daily dose of simvastatin (20 mg) and rosuvastatin (5 mg).
https://newsroom.csl.com/2024-03-28-Vafseo-R-approved-by-the-U-S-FDA-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-dialysis-dependent-adult-patients -
This was added as a gateway condition of the LTI target to ensure the ROIC is delivering an appropriate return each financial year as well as over the seven year rolling 0% 20% 40% 60% 80% 100% average period and aligns with shareholder outcomes.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
Biotech leader CSL has manufacturing centers, sales offices, and locations to serve patients and public health around the globe.
https://www.csl.com/we-are-csl/worldwide-locations -
For our executive KMP in 2019, the Board has approved an average 4% increase in Fixed Reward, no increase in STI and an average 30% increase 0% 20% 40% 60% 80% 100% in LTI targets to recognise that our executive KMP LTI component is significantly below global market comparators.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
68 CSL Limited Annual Report 2017 200 60% 35% 35% 35% 160 43% 43% 43% 43% 43% 60% 120 43% 43% 43% 43% 43% 80 35% 35% 35% 40 120% 70% 85% 70% 85% 85% 70% 85% 85% 0 L Reed L Reed G Boss G Boss G Naylor G Naylor R Repella R Repella D Lamont D Lamont P Perreault P Perreault V Romberg V Romberg K Etchberger K Etchberger A Cuthbertson A Cuthbertson
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
The ROIC measure as the hurdle for our LTI Plan, has been chosen because it is a business critical (high ROIC equals high performance), single (preferred over two 0% 20% 40% 60% 80% 100% measures), and is an absolute return measure (preferred over relative), which is easily understood by shareholders and ● 2019 Total Fixed Reward management alike.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
Ready for a challenge? CSL's Summer Internship Program offers roles in Engineering, Manufacturing, Research & Development, Business Operations, and more
https://www.csl.com/careers/early-careers-at-csl/internships/internships-in-the-us -
At-home subcutaneous therapy advances treatment options for patients and marks a milestone in 40 years of delivering on CSL's promise to the HAE patient Community
https://newsroom.csl.com/2022-09-26-CSL-Receives-Manufacturing-and-Marketing-Authorization-in-Japan-for-Berinert-R-S-C-Injection-2000,-as-a-Medicine-for-prevention-of-Acute-Hereditary-Angioedema-HAE-attacks -
Additionally, less than half of patients surveyed said they are very/somewhat knowledgeable about how different CIDP treatment options work (40%) or about how different CIDP treatment options are administered (45%). "
https://newsroom.csl.com/2024-01-16-Harris-Poll-Survey-Finds-People-Receiving-Treatment-for-CIDP-Are-Interested-in-Exploring-More-Convenient-Treatment-Options